PTC Therapeutics Boosts Workforce with Employee Equity Awards and Stock Options

PTC Therapeutics Expands Workforce with Employee Equity Awards

PTC Therapeutics, Inc. announces the approval of stock options and restricted stock units (RSUs) for five new employees, marking a strategic move to bolster its workforce and align employee interests with company growth. The recent awards encompass 3,825 stock options and 4,385 RSUs, granted on December 16, 2025. These equity incentives comply with Nasdaq Listing Rule 5635(c)(4), underscoring PTC's commitment to adhering to regulatory standards while enhancing its talent acquisition efforts. The exercise price for the stock options is set at $75.42 per share, reflecting the company's closing price on the grant date, indicative of PTC's market position.

The structure of the options and RSUs is designed to foster long-term commitment among employees. The stock options will vest over four years, with 25% becoming available on the first anniversary of each employee’s hire date, followed by quarterly vesting of the remaining shares. Similarly, the RSUs will follow a four-year vesting schedule, further incentivizing employees to contribute to PTC's long-term success. Such measures not only reward new hires but also align their performance with the company's strategic goals of discovering and commercializing innovative treatments for rare disorders.

PTC Therapeutics is dedicated to improving patient outcomes through its innovative therapies targeting unmet medical needs. The company’s robust pipeline of transformative medicines showcases its commitment to addressing the challenges faced by individuals with rare disorders. By expanding its workforce with equity incentives, PTC reinforces its position as a leader in the biotechnology sector, leveraging scientific expertise and a global infrastructure to deliver best-in-class therapies. This approach signifies PTC's ongoing dedication to not only advancing its mission but also fostering a motivated and invested workforce.

In addition to its strategic hiring practices, PTC encourages interested parties to explore further information about its initiatives and developments through its website and social media channels. For inquiries, investors can reach out to Ellen Cavaleri, while media-related questions can be directed to Jeanine Clemente. This outreach reflects PTC's commitment to transparency and engagement with stakeholders as it continues to pursue its vision in the biotechnology landscape.